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Background. The association of systemic sclerosis (SSc) and haematological cancers was reported in a large number of case reports
and cohort studies, describing SSc patients with highly heterogeneous clinical pictures. Objective. We reviewed the literature to
better describe SSc patients with haematological malignancies. Methods. SSc cases complicated by haematological malignancies
described in the world literature were collected; other 2 cases referred to our centre were reported. Results. One hundred-thirty SSc
subjects were collected from 1954 up to date. The mean age of patients at cancer diagnosis was 56.1 ± 16.7 years; 72% of patients
were females. In 60% of cases, the diagnosis of haematological malignancy was described within 5 years of SSc diagnosis. In 7.8% of
cases, coexistence of Sjo¨gren’s syndrome or other autoimmune disorders was cited. Sixty-six cases with lymphoma (in the majority
of cases B-cell neoplasms), 28 with leukaemia (chronic lymphocytic form in 9), 14 with multiple myeloma plus one solitary IgM
plasmocytoma, and 16 with myeloproliferative disorders were found. No specific SSc subsets seem to be related to haematological
malignancies. Conclusions. We remarked the importance of clinical work-up in SSc, in order to early diagnose and treat eventual
occult haematological malignancies, especially during the first years of the disease.
1. Introduction
The association between malignancies and connective tissue
diseases was widely reported in literature [1]; namely, sys-
temic sclerosis (SSc) has showed relatively high incidence
of lung, breast (contrasting data), and haematological can-
cers, as demonstrated by meta-analysis on population-based
cohort studies [2, 3]. However, these studies usually reported
the frequencies of specific malignancies in the course of
SSc, without further characterization of the patients. In this
respect, the subset of “haematological tumours” included dif-
ferent types ofmalignancies that generally were not described
in detail. On the other hand, a large number of case reports
may be found in literature [4–54], describing SSc patients
with highly heterogeneous clinical pictures complicated by
the onset of cancer. These reports could potentially contain
detailed data that are not included in registry or large cohort
studies [55–67].
The haematological neoplasms originate by the myeloid
or the lymphoid cell lines, historically named leukaemias or
lymphomas, based on the prevalent location in the blood
or the lymph nodes, respectively. Afterwards, more than 70
nosological entities were identified, classified according to
the 2008 World Health Organization (WHO) classification
of neoplasms of the hematopoietic and lymphoid tissues, on
the basis of the recognition of distinctive features in terms of
morphology, clinical picture, immunophenotype, and genetic
and molecular characteristics [68]. Indeed, the systematic
categorization of the haematological malignancies evolved
during the decades from the Rappaport classification of 1966
to theWHO classification in 2001 [69], lastly updated in 2016
[70], transposing the new knowledge achieved in the field of
histology and cytogenetic/immunohistochemical profiling of
malignancies.
In these lights, the known association between SSc and
haematological malignancies should be better characterized,
especially as regards eventual associations between SSc fea-
tures and specific type of blood neoplasms.Moreover, specific
SSc subsets might be associated with peculiar haematological
cancers, besides other comorbid predisposing conditions.
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Therefore, we aimed to collect all SSc cases complicated by
haematological malignancies described in the world litera-
ture, searching eventual specific clinical patterns.
2. Patients and Methods
We analysed the whole SSc patients’ cohort, recruited in our
Rheumatology Centre, including 454 cases referred to our
university-based hospital from 1 January 2003 to 31December
2016, in order to find the patients who presented haemato-
logical neoplasms in their clinical history, after SSc diagnosis.
For all patients, detailed clinical records were available, which
eventually comprehended the documentation regarding the
haematological diseases.
Secondly, the electronic databases, including PubMed,
Embase, Scopus,Web of Science, SciELO, J-Stage, andGoogle
Scholar, were searched for studies that described the cases
with the association between haematological cancers and
SSc, including all available previous articles and non-English
reports. Search terms were “systemic sclerosis” or “sclero-
derma” and “h(a)ematological cancer” or “lymphoma” or
“leuk(a)emia”. Myeloproliferative disorders (search terms:
“myelofibrosis”, “chronic myelogenous leukaemia”, “poly-
cythemia vera”, “essential thrombocytemia”) were also con-
sidered, as well as “MGUS”. All available data included
in the published studies were analysed, evaluating all the
information useful for patients’ clinical profiling.
We considered all SSc patients who developed blood
cancers; otherwise, the cases describing SSc onset after the
diagnosis of haematological cancer were excluded. Likewise,
the studies that did not exactly indicate the timing of
SSc and cancer diagnoses were excluded. On the contrary,
the patients with contemporary or very close onset of the
two pathologic conditions (blood cancer diagnosis within
1 year from SSc diagnosis) were registered as patients with
“probable paraneoplastic” syndrome. Finally, we did not
consider studies regardingmorphea or localized scleroderma
nor sclerodermiform syndromes following antineoplastic
treatments.
3. Case Reports
3.1. Case 1. A nonsmoker, 35-year-old male patient referred
to our centre in 2008 and received a new diagnosis of SSc.
The onset of the disease was few months before, featured
by skin thickening of face, hands, forearms, and chest;
skin ulcers or calcinosis was absent. He complained of
Raynaud’s phenomenon, fatigue, and mild sicca syndrome.
No anti-topoisomerase I or anti-centromere autoantibodies
were found (ANA 1 : 640 speckled), while anti-Ro/SSA and
anti-SSB were present (secondary Sjo¨gren’s syndrome). He
presented typical oesophageal dyskinesia and interstitial lung
disease with reduction of the forced vital capacity to 69%
and of the lung diffusion for the carbon monoxide to 33%.
Heart function was normal, and no signs of pulmonary
hypertension were found, while a slight increase of creatine-
kinase was reported. At chest high-resolution CT (HRCT)
performed within the first year of follow-up, an enlarge-
ment of the thymic shape emerged; the histology confirmed
the presence of thymic hyperplasia; thus, the gland was
removed, also hoping to counteract SSc progression [71].
After 2 years, the patient presented a deterioration of dyspnea
with dry cough, extension of skin thickness to the whole
body, increased fatigue, mild fever, and body weight loss. A
further chest HRCT revealed a new mediastinal enlargement
due to adenopathy (Figure 1); primary mediastinal B cell
lymphoma (a type of diffuse large B cell non-Hodgkin
lymphoma, NHL) was diagnosed by means of video-assisted
thoracoscopic surgery (VATS) lymph node biopsy. The stan-
dard CHOP-R (cyclophosphamide, hydroxydaunorubicin,
vincristine, prednisone, and rituximab) regimen was chosen;
however, after few months, before any clinical improvement,
the patient died from sepsis.
3.2. Case 2. A 72-year-old woman referred to our centre in
2012 from another hospital, where she was followed for SSc.
The disease’s onset dated back to 28 years before. Among
SSc features, we emphasize the presence of pulmonary arte-
rial hypertension, treated with sildenafil and, successively,
ambrisentan. Calcinosis, telangiectasias, sclerodactyly, and
anti-centromere antibodies, but not dysphagia nor interstitial
lung disease, were found. As comorbidity, the patient pre-
sented severe lower limb arteriopathy obliterans, responsible
for digital gangrenous lesions.Moreover, patient’s history was
marked by the diagnosis of low-grade tubular breast carci-
noma in 2006; then, she underwent right quadrantectomy. Six
years later, X-ray scan revealed a 2 cm pulmonary opacity in
the right lower lobe. After chest CT confirmation, lobectomy
was performed; the histological analysis diagnosed an extra-
nodal marginal mature B cell lymphoma (BALToma). Given
the absence of metastasis, no radio-/chemotherapy was con-
sidered necessary after the lung resection. To date, the patient
is doing well, without presenting recidivism.
4. Review of the Literature
Table 1 summarized all cases of SSc patients complicated by
haematological malignancies found in literature [4–67]; the
studies that do not give any information about SSc features
and/or haematological cancer types were excluded. Both case
reports and cohort studies were included, even though, usu-
ally, only the first ones reported complete description of the
clinical histories. To the best of our knowledge, 130 (including
our 2 cases) subjects affected by SSc and haematological
cancer were collected, from the first case described in 1954
up to date. Majority of patients were from Europe and USA
and were Caucasian, while 18% of persons were of Asian
ethnicity, coming from the Far Eastern Countries. The mean
age of patients was 56.1±16.7 years, without gender difference
as regards age, with the higher prevalence of cases in the
sixth decade. 72% of the cases were women. The diagnosis
of haematological malignancies was frequently close to SSc
diagnosis: indeed, in about 30% of cases, scleroderma could
be considered as “probable paraneoplastic,” while for other
30%of patients the cancerwas diagnosedwithin 5 years of SSc
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(a) (b)
Figure 1: Radiological chest studies of our patient number 1. (a) Two scans of high-resolution CT, showing the mediastinal adenopathic
masses. (b) Standard X-ray and total body PET scan, showing diffuse high-metabolism adenopathies.
diagnosis. Sporadic observations of blood cancer were also
reported during the further years, even after several decades.
Among SSc patients with haematological malignancies,
the diffuse skin subset was reported in 28% of cases. As
regards serology, anticentromere and anti-Scl70 autoantibod-
ies were equally found; of note, a relevant percentage (29%)
of specific anti-nuclear autoantibodies (ANA) was observed.
Organ SSc involvement was not frequently described; any-
way, no peculiar associations may be found, because the
malignancies could be observed both in SSc patients with
diffuse skin involvement and interstitial lung disease and in
the “CREST” patients’ subset. In a few cases, overlapping
Sjo¨gren’s syndrome (a disease with well-known increase
of haematological cancer risk) was suspected or clearly
reported; moreover, rheumatoid arthritis was recognized in 2
patients, porphyria cutanea tarda in other 2, and pemphigus
vulgaris in 1. Finally, only in few patients a detailed clinical
history was available, giving the possibility of identifying
other eventual cancer risk factors (i.e., smoking).
As regards haematological malignancies, we collected
66 cases with lymphoma (including our 2 cases), 28 with
leukaemia, 14 with multiple myeloma (plus one solitary IgM
plasmocytoma), and 16 with myeloproliferative disorders;
in 3 the exact diagnosis was not expressed. Many types of
lymphoma were reported, often not better specified than
the mere definition of “non-Hodgkin lymphoma”; in the
other cases, the diffuse large B cells lymphoma was the most
frequent (8 cases plus 1, our case). With the exception of few
patients, all lymphomas described are classifiable as mature B
cells neoplasms; in fact, we registered only 3 lymphomas of T
cells and 2 from histiocytic cells, while 6 cases of Hodgkin’s
lymphoma were found.
Considering the 28 cases developing leukaemia, 9
patients showed the chronic lymphocytic form. T cells
leukaemia was present in only 2 persons; 8 cases were not
better specified. Finally, among myeloproliferative disorders,
4 cases of myelofibrosis and 11 of chronic myelogenous
leukaemia were found; just one patient presented poly-
cythemia vera, while no cases of essential thrombocythemia
were found.
The clinical courses of the treated patients may be
divided into 2 prognostic patterns, substantially equivalent
in percentage: (1) rapid improvement up to remission, often
associated with SSc features amelioration; (2) rapid deterio-
ration until death from infectious causes. The latter pattern
was invariably observed in patients over 50 of age; no other
clinical features useful for prognostic purposes were found.
5. Discussion
It is known from the literature that the incidence of haema-
tological malignancies is significantly increased in SSc [1–
3]; in this review, we tried to better define this statistical
association gathering together all SSc cases complicated by
blood cancers previously described.We found that themajor-
ity of cases presented the B cells non-Hodgkin lymphoma
(especially the diffuse large B cells lymphoma, as well as
our case number 1), the multiple myeloma, and the chronic
lymphocytic leukaemia; furthermore, also myeloproliferative
disorders were frequently described in the course of SSc.
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Figure 2: Distribution of SSc patients with haematological malignancies on the basis of age at tumour diagnosis (a) and SSc disease duration
(b).
Besides the heterogeneity of the cases reported in literature,
we found that the diagnosis of haematological neoplasms
was a precocious event in SSc patients’ clinical histories,
particularly within 5 years of SSc diagnosis in the majority of
cases (Figure 2). Therefore, given the possibility of successful
treatments for a potentially aggressive disease, the clinical-
serological surveillance for haematological malignancies in
SSc patients should be addressed.
Regarding the demographic characteristics of the SSc
patients with blood cancers, we found a higher frequency
of males (28%) in comparison to the female/male ratio
previously described in large SSc case series [72], probably
because of the higher NHL incidence among male subjects
[73].
Even though anecdotal in several patients, we underline
the coexistence of other autoimmune disorders or pathologic
conditions known for their increased risk of cancer. Indeed,
the omission of relevant anamnestic information in the
descriptions of patients reported in literature is presum-
able, especially for the registry/large cohort-based studies
designed for the statistical analysis of cancers epidemiology.
As regards serology, the presence of a specific ANA in
SSc patients with haematological cancers was found in 29%
of cases, more than generally reported in previous cohort
studies [72]. In this respect, Altintas et al. [74] detected ANA
in more than 20% of 179 patients affected by lymphomas,
even though the majority of them did not show autoimmune
diseases. Furthermore, in an elegant study byGuyomard et al.
[75], 347 NHL patients and 213 controls were investigated by
means of indirect immunofluorescence technique on Hep2
cells. ANA were significantly more frequent in the first
group (19% versus 5.6%), before any treatment, particularly
in presence of follicular or mantle B cell lymphomas. The
latter are characterized by a high rate of cells proliferation and
a large number of apoptotic cells, leading to the exposition
of large amount of nuclear antigens, eventually targeted by
patients’ immune system.
The association between autoimmune diseases and
haematological neoplasms is an intriguing question; indeed,
more than 10% of lymphoidmalignancies occur in the setting
of an autoimmune disorder [76]. Accumulated evidences
indicate that autoreactive B cells are more prone to undergo
malignant transformation. In parallel, the chronic activation
of the inflammatory response due to autoantigen-driven
immune stimulation in specific organ tissues (i.e., the parotid
gland in Sjo¨gren’s syndrome) is associated with an increased
risk of lymphomas [76, 77]. Furthermore, the epidemiological
data from large population studies on other autoimmune
diseases, such as rheumatoid arthritis or systemic lupus
erythematosus, showed a high risk of B cells haematological
neoplasms, particularly the diffuse large B cell lymphoma
[78, 79]. Consistently, in SSc, we found a clear-cut prevalence
of B cells versus the T cells cancers, suggesting that the
systemic autoimmune activation plays a pivotal role in the
carcinogenetic evolution.
Besides the evidences of pathogenetic and statistical links
between SSc and haematological malignancies [1–3], the
exact mechanism responsible for cancers is not understood.
In other autoimmune disorders specific etiologic factors (i.e.,
HCV for mixed cryoglobulinemia [80]) lead to persistent
stimulation of the immune system and, eventually, to lym-
phomagenesis. Differently, SSc etiology remains obscure,
despite the probable role of a few infectious triggers able
to chronically infect immune cells [81]. Overall, a deeper
knowledge of the SSc etiopathogenetic processes, probably
different for several disease’s subsets, could help to better
quantify the risk for different types of cancers, including
haematological neoplasms.
Since the majority of patients described in the present
study developed the tumours in the first years of the disease
(Figure 2), including our first case, the possible iatrogenic
effect of immunosuppressors may be easily excluded. On the
contrary, it was hypothesized that the immune alterations in
the early phase of SSc present a different pattern, which tends
to change during the disease’s follow-up [82].
We previously demonstrated a high prevalence of thymic
hyperplasia in SSc patients, particularly during the first years
of the disease [71]. Given the fundamental role of the thymus
in the maturation of T lymphocytes, it might be assumed that
a pathological alteration of the thymic microenvironment
could lead to a deficient or incomplete T cell maturation,
which might have a role in the immunological alterations
of SSc etiopathogenesis. Nonetheless, the autoreactivity of T
cells strictly involves also B cells that produce a number of
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different autoantibodies, which in turn stimulate fibroblasts’
toll-like receptors-4 [83] and induce endothelial dysfunction
[84]. B cell infiltrates may be detected in SSc patients’ skin
or in affected areas of the lungs, so giving the rationale for
the therapeutic use of rituximab [85].Therefore, even though
T cells are considered the driving force of the autoimmune
pathogenesis in SSc, it is not surprisingly the observation of
an increased risk for B cells-derived malignancies.
Upon the onset of autoimmune responses, lymphoid
tissues undergo histological changes due to the remodelling
of the tissue architecture in parallel with the phenotypic
transformations of immune cell populations. Recently, San-
galetti et al. [76] hypothesized that an erroneous remodelling
of the stromal microenvironment in secondary lymphoid
organs could facilitate malignant transformation of lympho-
cytes, in presence of persistent immune stimulation. Thus,
lymphomagenesis would be a result of disrupted myeloid
and lymphoid function in lymphoid tissues that harbour
autoreactive proliferating T and B cells. In this respect, our
paradigmatic case developed a lymphoma that probably rose
in the thymus, which was histologically disrupted by the
preexistent thymic hyperplasia.
In SSc patients, several studies demonstrated the activa-
tion status of the peripheral B lymphocytes with an impaired
percentage of apoptotic cells compared to healthy controls
[86]. Moreover, Wang et al. [87] found that the levels of his-
tone acetylation and methylation (responsible for increased
gene transcription) in B cells from SSc patients correlate with
disease activity. Furthermore, serum concentrations of BAFF
and APRIL, cytokines regulating B cell activity, survival,
and proliferation, are found elevated in SSc in comparison
with healthy controls, particularly in patients with active
or severe disease [86]. In this light, we might assume that
the sclerodermic patients with poorly controlled disease (an
occurrence more probable in the early phase of SSc, like
in our first case) are more prone to develop haematological
malignancies in their clinical histories.
In SSc, the increase of B cells survival and activation
sounds apparently in contrast with the finding of augmented
Fas (CD95) expression on the surface of memory B cell that
facilitate Fas-mediated apoptosis. However, the incessant loss
of these lymphocytes is coupled to the increased production
of naive B cells and plasma cells in order to maintain B
cell homeostasis [88]. Therefore, the amplification of the
percentage of less mature B lymphocytes understandably
leads to a major risk for lymphoid carcinogenesis.
Finally, as opposite scenario, we briefly mention the
possibility that cancer mutations might trigger SSc itself, at
least in patients with anti-RNApolymerase III autoantibodies
[89]. Neoplasms could harbour missense mutations in the
gene coding for the polymerase III polypeptide A, leading
to the production of an altered protein. The latter could
stimulate an immune response and, possibly, a cross-reaction
against the normal protein; this immune response could be
relevant in the pathogenesis of a subset of SSc [90].
The present study shows a few limitations. Firstly, even
though this review included the higher possible number of
studies, several cases of SSc complicated by blood cancers
described in literature were lost [91, 92], because of the
unavailability of the necessary information for the purposes
of our study. This limitation may be exceeded only with
further studies designed ad hoc, including large case series.
Secondly, our review included a number of case reports,
in which contemporaneous SSc and haematological malig-
nancy are more likely to be reported than cases where
the diagnoses are far apart. In particular, SSc patients who
suffered from haematological malignancies longer after SSc
onset were more unlikely to be published because it was
difficult to emphasize the relationship of ‘SSc and haema-
tological malignancies.’ However, also SSc cohort studies
seem to confirm the higher incidence of blood cancers
in the first years of SSc. Anyway, the eventual exposure
to immunosuppressive therapy in SSc patients with longer
disease duration could be considered a further risk factor for
cancer development.
In conclusion, SSc may be complicated by several types
of cancers, including haematological malignancies. More
frequently, B cells-derived lymphomas and leukaemias may
be diagnosed in the first years of the disease and represent
a significant warning for patients’ prognosis. To date, no
specific SSc features could predict which subjects present
major risk for blood cancer; thus, a careful surveillance of SSc
patients should be addressed.
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